Xilio Therapeutics, Inc.: shareholders and insiders

XLONASDAQHealthcare · Pharmaceutical Preparations

Price

$7.51

November 19, 2026Market cap $53M

What Ploutos Investor adds for Xilio Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 2 fiscal years, from 2024
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Nov 20, 2025 to Oct 2, 2026, from their own Form 4 filings.

8 Form 4s

Bought on the market

$44.0K

1 person

Sold on the market

$5.7K

2 people

From Nov 20, 2025 to Nov 20, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan100%
  • The rest0%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 20, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·bought $44.0K by 1 person·sold $5.7K by 2 people

  • 2025: no buys, no sales
  • 2026: bought $44.0K by 1 person, sold $5.7K by 2 people
  • Mar 26, 2026James Samuel Shannon
    Kind
  • Jan 2, 2026Christopher James FrankenfieldChief Financial Officer
    Kind10b5-1
  • Jan 2, 2026Kevin M. BrennanSVP, FINANCE AND ACCOUNTING
    Kind10b5-1

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 12, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by XLO's officers and directors from 2021 up to November 19, 2025, 5 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

9 Holders over 5%Nov 12, 2026 Latest filing
  • Gilead Sciences
    Share of class19.9%
  • BCLS II Equity Opportunities, LPwith 2 more persons
    Share of class9.99%
  • Coastlands Capital LPwith 4 more persons
    Share of class9.99%
  • Orbimed Advisorswith 1 more person
    Share of class9.99%
  • Sirenia Capital Management LPwith 1 more person
    Share of class9.90%
  • StemPoint Capital LPwith 2 more persons
    Share of class9.50%
  • AbbVie Inc.
    Share of class9.00%
  • Adage Capital Management, L.P.with 2 more persons
    Share of class7.06%
  • Frazier Life Sciences Public Fund, L.P.with 9 more persons
    Share of class6.70%
Fell to 5% or less (2)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • Point72 Asset Management, L.P.0.00%May 15, 202613G/A
  • Rock Springs Capital Management LP0.00%May 15, 202513G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Citadel Advisors (Griffin)
    In the quarter-57%
  • Renaissance Technologies
    In the quarter-0.9%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 5.67% of its shares outstanding were held short, -2.4% since the report before.

Shares held short
400.3K
5.67%
Since the report before410.1K on Sep 30, 2026
-2.4%
41.2
9,727
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 25.3K
  • Nov 15, 2023: Shares held short 29.0K
  • Nov 30, 2023: Shares held short 54.1K
  • Dec 15, 2023: Shares held short 18.6K
  • Dec 29, 2023: Shares held short 1,403
  • Jan 12, 2024: Shares held short 6,455
  • Jan 31, 2024: Shares held short 1,591
  • Feb 15, 2024: Shares held short 33.7K
  • Feb 29, 2024: Shares held short 21.2K
  • Mar 15, 2024: Shares held short 57.6K
  • Mar 28, 2024: Shares held short 54.2K
  • Apr 15, 2024: Shares held short 379.5K
  • Apr 30, 2024: Shares held short 456.5K
  • May 15, 2024: Shares held short 419.1K
  • May 31, 2024: Shares held short 445.0K
  • Jun 14, 2024: Shares held short 75.0K
  • Jun 28, 2024: Shares held short 117.7K
  • Jul 15, 2024: Shares held short 144.9K
  • Jul 31, 2024: Shares held short 118.6K
  • Aug 15, 2024: Shares held short 111.3K
  • Aug 30, 2024: Shares held short 31.0K
  • Sep 13, 2024: Shares held short 14.8K
  • Sep 30, 2024: Shares held short 140.1K
  • Oct 15, 2024: Shares held short 104.7K
  • Oct 31, 2024: Shares held short 396.1K
  • Nov 15, 2024: Shares held short 42.0K
  • Nov 29, 2024: Shares held short 175.3K
  • Dec 13, 2024: Shares held short 119.4K
  • Dec 31, 2024: Shares held short 384.1K
  • Jan 15, 2025: Shares held short 213.1K
  • Jan 31, 2025: Shares held short 199.0K
  • Feb 14, 2025: Shares held short 1.81M
  • Feb 28, 2025: Shares held short 694.6K
  • Mar 14, 2025: Shares held short 575.4K
  • Mar 31, 2025: Shares held short 644.5K
  • Apr 15, 2025: Shares held short 562.3K
  • Apr 30, 2025: Shares held short 351.2K
  • May 15, 2025: Shares held short 1.22M
  • May 30, 2025: Shares held short 791.5K
  • Jun 13, 2025: Shares held short 2.62M
  • Jun 30, 2025: Shares held short 3.32M
  • Jul 15, 2025: Shares held short 3.34M
  • Jul 31, 2025: Shares held short 3.82M
  • Aug 15, 2025: Shares held short 4.31M
  • Aug 29, 2025: Shares held short 4.30M
  • Sep 15, 2025: Shares held short 4.92M
  • Sep 30, 2025: Shares held short 5.16M
  • Oct 15, 2025: Shares held short 5.25M
  • Oct 31, 2025: Shares held short 6.16M
  • Nov 14, 2025: Shares held short 6.91M
  • Nov 28, 2025: Shares held short 6.68M
  • Dec 15, 2025: Shares held short 3.09M
  • Dec 31, 2025: Shares held short 2.17M
  • Jan 15, 2026: Shares held short 2.09M
  • Jan 30, 2026: Shares held short 2.14M
  • Feb 13, 2026: Shares held short 2.16M
  • Feb 27, 2026: Shares held short 2.11M
  • Mar 13, 2026: Shares held short 2.23M
  • Mar 31, 2026: Shares held short 182.5K
  • Apr 15, 2026: Shares held short 174.3K
  • Apr 30, 2026: Shares held short 163.0K
  • May 15, 2026: Shares held short 171.4K
  • May 29, 2026: Shares held short 165.3K
  • Jun 15, 2026: Shares held short 173.5K
  • Jun 30, 2026: Shares held short 174.6K
  • Jul 15, 2026: Shares held short 268.2K
  • Jul 31, 2026: Shares held short 425.9K
  • Aug 14, 2026: Shares held short 421.9K
  • Aug 31, 2026: Shares held short 418.3K
  • Sep 15, 2026: Shares held short 413.0K
  • Sep 30, 2026: Shares held short 410.1K
  • Oct 15, 2026: Shares held short 400.3K

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading37.5% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 37.5% of the shares in the reported trades were short sales, against 37.3% in the 14 before.

Last 14 sessionsNov 2, 2026 – Nov 19, 2026
37.5%
The 14 beforeOct 13, 2026 – Oct 30, 2026
37.3%
Change
+0.2 pts
Short sales a dayon average, of 3,729 shares
1,398
More than atof 3,666 US-listed companies, same days
15%
Median of alleight in ten from 34.5% to 63.8%
50.4%
  • Oct 13, 2026: Short sales 28.5%
  • Oct 14, 2026: Short sales 52.9%
  • Oct 15, 2026: Short sales 35.1%
  • Oct 16, 2026: Short sales 16.9%
  • Oct 19, 2026: Short sales 19.8%
  • Oct 20, 2026: Short sales 39.2%
  • Oct 21, 2026: Short sales 46.8%
  • Oct 22, 2026: Short sales 30.9%
  • Oct 23, 2026: Short sales 37%
  • Oct 26, 2026: Short sales 36.4%
  • Oct 27, 2026: Short sales 47.5%
  • Oct 28, 2026: Short sales 37.8%
  • Oct 29, 2026: Short sales 12.4%
  • Oct 30, 2026: Short sales 30.8%
  • Nov 2, 2026: Short sales 52.4%
  • Nov 3, 2026: Short sales 33.7%
  • Nov 4, 2026: Short sales 51.8%
  • Nov 5, 2026: Short sales 33.2%
  • Nov 6, 2026: Short sales 59.4%
  • Nov 9, 2026: Short sales 34%
  • Nov 10, 2026: Short sales 33.8%
  • Nov 11, 2026: Short sales 21.9%
  • Nov 12, 2026: Short sales 25.7%
  • Nov 13, 2026: Short sales 36.7%
  • Nov 16, 2026: Short sales 31.7%
  • Nov 17, 2026: Short sales 36.5%
  • Nov 18, 2026: Short sales 54.9%
  • Nov 19, 2026: Short sales 0.6%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

14.94M Insiders' shares258.31% Of the company
  • Gilead Sciences, Inc.TenPercentOwner
    Directly9.11M
  • Atlas Venture Associates Opportunity I, L.P.TenPercentOwner
    Directly2.02M
  • Atlas Venture Fund XI, L.P.TenPercentOwner
    Directly2.02M
  • Rene RussoPRESIDENT AND CEO
    Directly281.2K
  • Christopher James FrankenfieldChief Financial Officer
    Directly24.8K
  • James Samuel ShannonDirector
    Directly10.0K
  • Kevin M. BrennanSVP, FINANCE AND ACCOUNTING
    Directly6,371

A lower bound: it counts only the 7 officers and directors with a market trade since Nov 21, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

3 ETFs holding it0.01% The largest weight (IWC)
  • IWCiShares Micro-Cap ETF
    Weight in the fund0.01%
  • VXFVanguard Extended Market Index Fund
    Weight in the fund0.00%
  • VTIVanguard Total Stock Market Index Fund
    Weight in the fund0.00%

3 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

27 Managers, Q2 2026$33M Value of their positions
  • Q3 2025: Managers 36
  • Q4 2025: Managers 37
  • Q1 2026: Managers 24
  • Q2 2026: Managers 27

Institutional investors by quarter

The fund managers holding XLO, quarter by quarter, from Q4 2021 to Q2 2025, 15 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 27 managers held 3.45M shares, worth $33M. During the quarter 10 opened a position, 6 closed one, 4 added and 3 trimmed.

The largest holders, Q2 2026

  • Bain Capital Life Sciences Investors
    In the quarter
  • Gilead Sciences
    In the quarter
  • Orbimed Advisors
    In the quarter
  • Frazier Life Sciences Management
    In the quarter
  • Stonepine Capital Management
    In the quarter+252%
  • Vanguard Capital Management
    In the quarter+44%
  • Sio Capital Management
    In the quarter
  • Adage Capital Partners Gp
    In the quarter
  • Merck
    In the quarter
  • Renaissance Technologies
    In the quarter+29%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Xilio Therapeutics's filings show?

Who buys and sells is one part of Xilio Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about XLO's shareholders

Didn't find what you were looking for?

Ask us
Have XLO's insiders bought or sold?

From Jun 12, 2026 to Oct 2, 2026 Xilio Therapeutics's insiders reported no purchase or sale of shares on the market.

Which well-known managers hold XLO?

2 of the managers we track held the shares on Sep 30, 2026. The largest position was Renaissance Technologies's, worth $600.0K.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.